Analysts at Evercore ISI assumed coverage on shares of Omada Health (NASDAQ:OMDA - Get Free Report) in a report issued on Tuesday, MarketBeat reports. The firm set an "outperform" rating and a $21.00 price target on the stock. Evercore ISI's target price would suggest a potential upside of 12.72% from the stock's current price.
Several other equities research analysts have also weighed in on the company. JPMorgan Chase & Co. assumed coverage on Omada Health in a report on Tuesday. They issued an "overweight" rating and a $19.00 target price for the company. Needham & Company LLC assumed coverage on shares of Omada Health in a research report on Tuesday. They issued a "buy" rating and a $23.00 price target on the stock. Morgan Stanley assumed coverage on shares of Omada Health in a report on Tuesday. They set an "overweight" rating and a $25.00 price objective for the company. The Goldman Sachs Group began coverage on shares of Omada Health in a research note on Tuesday. They issued a "buy" rating and a $29.00 target price on the stock. Finally, Wall Street Zen upgraded shares of Omada Health to a "hold" rating in a report on Monday, June 16th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $23.57.
View Our Latest Stock Analysis on OMDA
Omada Health Stock Up 2.9%
Shares of NASDAQ:OMDA traded up $0.53 on Tuesday, reaching $18.63. The company had a trading volume of 344,526 shares, compared to its average volume of 1,585,299. Omada Health has a twelve month low of $14.14 and a twelve month high of $28.40.
About Omada Health
(
Get Free Report)
Omada's mission is to bend the curve. Our hope is that, one day, tomorrow's epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms.
See Also
Before you consider Omada Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omada Health wasn't on the list.
While Omada Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
